Monoconal Antibody Design Challenge

Bighat is building to overcome the inevitable problems that you have designing antibodies and encroaching therapeutics. We've developed technologies that work quite well at discovering very tightly binding, high quality anti monoclonal antibodies. But people want to be able to do more than you can just do with a monoconal antibody. And so really it's a spectrum from the type of target and the therapeutic hypothesis.